Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc.

LFCRยทNASDAQ

$5.67

+1.5%
HealthcareDrug Manufacturers - Specialty & Generic

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

At a Glance

Live Snapshot
Market Cap$212.68M
EPS-1.2700
P/E Ratio-4.46
Earnings Date07/31/2026
3Y-99.0%
5Y-99.0%
10Y-101.0%
3Y-108.0%
5Y-73.0%
10Y-85.0%
3Y-111.0%
5Y-84.0%
10Y-59.0%
LFCR

Lifecore Biomedical, Inc. Cash Conversion Engine

LFCR ยท NASDAQ
Net Income-38.72M
Depreciation & Amortization8.03M
Stock-Based Compensation10.16M
Change in Working Capital-4.70M
Others25.02M
Capital Expenditures-13.41M
Free Cash Flow-13.62M

Cash Flow Quality Analysis

FCF Conversion Rate

35.2%

Weak cash conversion. Significant portion of earnings not converting to cashโ€”review working capital trends and capital intensity.

CapEx Intensity

-6512.1%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

+24.9%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

-$4.70M

Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.

Cash Flow Quality Insight

Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.

Lifecore Biomedical, Inc. Cash Flow Statement

LFCR โ€ข NASDAQ

Lifecore Biomedical, Inc. Cash Flow StatementMay 2025May 2024May 2023May 2022May 2021May 2020May 2019May 2018May 2017May 2016May 2015May 2014May 2013May 2012May 2011May 2010May 2009May 2008May 2007May 2006
OPERATING ACTIVITIES
-38.7M
12M
-99.6M
-116.7M
-32.3M
-15.1M
411K
24.9M
10.7M
-11.4M
13.7M
19.3M
22.8M
13.1M
4.3M
4M
7.7M
13.5M
29.2M
8.7M
8M
8M
13.2M
18.1M
19.9M
18.8M
15.2M
12.4M
10.7M
9.4M
7.1M
7.1M
7.3M
5.6M
5.3M
3.4M
3.1M
3.2M
3.3M
3.2M
0.0
163K
357K
-6.8M
-7.9M
-5.4M
910K
-7.2M
2.5M
-9.9M
3.7M
3.7M
5.2M
-774K
2.5M
3.2M
2.6M
-611K
0.0
0.0
10.2M
6.2M
3.6M
2.6M
3.4M
2.4K
3.6M
4.4M
4M
3.5M
1.6M
1.4M
1.7M
1.9M
2M
1M
933K
0.0
0.0
0.0
25M
-22.4M
45.2M
83.4M
23.6M
12.4M
-2.9M
-4.6M
919K
32.8M
-3.2M
-9.7M
-11.8M
-5.8M
3.3M
165K
-2.1M
548K
-24M
-902K
(46K)
(72K)
(23K)
(441K)
(0.0)
(0.0)
(0.0)
(283K)
(2.8M)
(2.6M)
(150K)
(50K)
(5.6M)
-246K
(146K)
(652K)
(1.1M)
(0.0)
(0.0)
(0.0)
-4.7M
-3.7M
19.8M
-3.1M
9.8M
-27.7M
-1.2M
-10.1M
584K
-2.5M
3.3M
-779K
-4M
8.2M
-2.9M
-4.3M
-2.8M
837K
-10.5M
-87K
-206K
257K
-17.4M
-22.6M
16.5M
-17M
16M
19.8M
29.3M
21.8M
26.2M
21M
21.2M
22.2M
14.5M
7.5M
9.4M
17.5M
-2.1M
10.9M
INVESTING ACTIVITIES
-13.4M
-18.4M
-21.5M
-29.9M
-25.2M
-26.7M
-44.7M
-33.6M
-22.6M
-40.9M
-17.5M
-14.9M
-8.9M
-5.4M
-6.7M
-44.9M
-4.6M
-4.2M
-6.8M
-4.7M
(7M)
(0.0)
(16.7M)
(73.5M)
(0.0)
(2.4M)
-59.9M
-4.1M
-2.5M
-121K
(0.0)
(0.0)
(0.0)
-66.8M
(0.0)
(0.0)
-7K
-1.4M
-1.2M
-3.9M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(264K)
(0.0)
(0.0)
(0.0)
-18M
-1.4M
-5M
-30.7M
-74.8M
-67.4M
-45.8M
-14.6M
(0.0)
-991K
0.0
0.0
0.0
45.1M
0.0
0.0
7M
0.0
0.0
0.0
0.0
3M
3.4M
58.8M
52.1M
69.5M
38M
0.0
0.0
3M
0.0
0.0
0.0
-8.7M
12.9M
364K
545K
-2M
81K
-723K
1.1M
1.5M
-1.5M
0.0
0.0
-39.7M
101K
104K
50M
1.1M
-6.4M
-18.4M
-4.8M
(80M)
-12.3M
-23.9M
-96.8M
-35.6M
-25M
-41.6M
-34.4M
-13.3M
-10.4M
-44.1M
-29.4M
-42.8M
-12.3M
-20.2M
(42M)
-5.5M
FINANCING ACTIVITIES
23.9M
0.0
4.8M
0.0
0.0
30K
327K
56K
706K
322K
122K
-1.3M
3.4M
-4.9M
-1.1M
379K
379K
-18.4M
-4.7M
3.5M
-18.6M
2.2M
3.1M
-55.4M
7.5M
41.8M
54.9M
18.9M
-8.6M
15.6M
8.1M
-9.9M
-14.7M
39.2M
-3.9M
19.6M
0.0
0.0
7.3M
-1.1M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-5M
-1.2M
(0.0)
(0.0)
-19.5M
-7.4M
(0.0)
1.1M
5.3M
-6.3M
-1.6M
-10.9M
-1.8M
23.8M
-5.7M
-874K
-495K
-563K
456K
-8M
1.7M
234K
-320K
1.6M
2.9M
-630K
-75K
6.4M
7.5M
39.7M
-57M
-3.4M
40M
79M
13.3M
-8.8M
15.6M
8.2M
-7.2M
-19.3M
35.9M
-4.8M
19.7M
2M
-15.5M
2.1M
2.3M
CASH FLOW SUMMARY
-197K
-10.6M
17.4M
348K
742K
-912K
-1.8M
-2.5M
-4.5M
-4.2M
-116K
525K
-8.5M
14M
-19.7M
-15.6M
-937K
-18.2M
42M
7.6M
8.5M
19.1M
1.6M
1.3M
553K
1.5M
3.2M
5.4M
9.9M
14.1M
14.2M
13.7M
22.2M
8.1M
27.8M
43.5M
44.4M
62.6M
20.5M
12.9M
8.3M
8.5M
19.1M
1.6M
1.3M
553K
1.5M
2.9M
5.4M
9.9M
14.1M
14.2M
13.7M
22.2M
8.1M
27.8M
43.5M
44.4M
62.6M
20.5M
-13.6M
-18.1M
-38.9M
-52.5M
-8.8M
-43.7M
-28.7M
-13.8M
6.7M
-19.1M
8.6M
6.2M
12.4M
16.8M
7.8M
-37.4M
4.9M
13.3M
-8.8M
6.1M

SEC Filings

LFCR - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
10-Q

10-Q 2026 Q1

Q1

May 06, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 06, 2026
May 06, 2026
2026
DEF 14A

DEF 14A 2026

N/A

April 24, 2026
April 24, 2026
2026
8-K

8-K 2026

N/A

March 16, 2026
March 16, 2026
2026
8-K

8-K 2026

N/A

March 05, 2026
March 05, 2026
2026
8-K

8-K 2026

N/A

January 16, 2026
January 14, 2026
2026
8-K

8-K 2025

N/A

November 17, 2025
November 17, 2025
2025
10-Q

10-Q 2025 Q3

Q3

November 06, 2025
September 30, 2025
2025
8-K

8-K 2025

N/A

November 06, 2025
November 06, 2025
2025
8-K

8-K 2025

N/A

October 31, 2025
October 29, 2025
2025
Showing 1 to 10 of 456 filings